Lower-dose radiation safe for certain lower-risk, HPV-positive head and neck cancers

Regorafenib shows early promise in colorectal candidates unable to undergo chemo

Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia

Phase III SELECT trial shows lenvatinib to be effective in resistant thyroid cancer

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast cancer

Genomic sequencing helps identify best candidates for adjuvant chemo in colorectal cancer

Mantle cell lymphoma: A review of data and expert opinion from ASCO 2014

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in metastatic colorectal cancer

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early-stage HER2-positive breast cancer

First-line bevacizumab plus chemotherapy and cetuximab plus chemotherapy provide similar survival benefit for patients with metastatic colorectal cancer

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer